Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Eir
  6. /
  7. Brock A. McConnehey, DO
EIR
•Brock A. McConnehey, DO•April 2, 2021

Brock A. McConnehey, DO – FDA EIR, Apr 2, 2021

Record Details

An FDA inspection of clinical investigator Brock A. McConnehey, DO, associated with Northwest Clinical Trials in Boise, ID, was conducted from March 29 to April 2, 2021. This surveillance inspection, part of a high-priority mission under the Bioresearch Monitoring (BIMO) program and compliance program 7348.811 for Clinical Investigators and Sponsor-Investigators, focused on a clinical trial for an investigational drug for episodic migraine prevention, supporting an Investigational New Drug (IND) and New Drug Application (NDA). The inspection evaluated adherence to Good Clinical Practice regulations, specifically 21 CFR 312.60.

Key violations, documented in a Form FDA 483, included failure to conduct the investigation in accordance with the investigational plan. Specifically, one subject was randomized and dosed with the study drug while taking a prohibited concomitant medication, a clear protocol deviation. Furthermore, the site failed to report nausea as an adverse event in the electronic case report form (eCRF) for another subject and did not assess its severity, duration, outcome, or relatedness to the study drug. Additionally, there were significant data discrepancies between source documents and eCRFs regarding several concomitant medications and the severity and relatedness of adverse events.

Management, through the clinical investigator, stated plans to inform the sponsor of these deviations and implement a corrective and preventive action (CAPA) plan. This CAPA plan aims to review ongoing studies and prevent similar issues in future research. A formal written response to the FDA 483 was submitted by April 7, 2021. The inspection noted that no immediate corrections were made during the inspection period.

Company
Brock A. McConnehey, DO
Inspection date
April 2, 2021
Product type
drugs
Office
Center for Drug Evaluation and Research
Person
  • Sherri N. Rohlf (investigator)
View Company Profile

ID · f5e90d8e-d9d5-406e-be93-2f27bf1c4782

Violation Codes3
21 CFR 312.6021 CFR 312.62(b)21 CFR 312

Full citation text and observation details available on the Dashboard.

Other documents for Brock A. McConnehey, DO
  • 483 - 2021-04-02April 2, 2021

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Brock A. McConnehey, DO
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.